

You are cordially invited to attend a webconference:

ERLEADA[®] (apalutamide) For the Treatment of Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

PRESENTED BY

Kara Cossis, PA

Physician Assistant

Chesapeake Urology Associates, Baltimore, MD

WEBCONFERENCE

Tuesday, June 09, 2020 at 8:00 PM

Please use the URL below to register for the broadcast in advance and to access the broadcast: <http://www.inceptionmeetings.com/janssenwebconference>

Participant Dial In: (844) 217-2123/ Reference ID: Oncology

LEARNING OBJECTIVES:



Overview of mCSPC and Patient Identification



Summary of Indications, Clinical Trial Data, and Efficacy



Review of Safety Profile and Dosage & Administration

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Janssen Biotech, Inc., educational program using your preferred method of communication as indicated by you. This information may be shared with Janssen Biotech, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.

INDICATIONS

ERLEADA[®] (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with:

- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ischemic Cardiovascular Events — In a randomized study (SPARTAN) of patients with nmCRPC, ischemic cardiovascular events occurred in 4% of patients treated with ERLEADA[®] and 3% of patients treated with placebo. In a randomized study (TITAN) in patients with mCSPC, ischemic cardiovascular events occurred in 4% of patients treated with ERLEADA[®] and 2% of patients treated with placebo. Across the SPARTAN and TITAN studies, 6 patients (0.5%) treated with ERLEADA[®] and 2 patients (0.2%) treated with placebo died from an ischemic cardiovascular event. Patients with current evidence of unstable angina, myocardial infarction, or congestive heart failure within 6 months of randomization were excluded from the SPARTAN and TITAN studies.

Please see additional Important Safety Information on next page.

Please see accompanying full Prescribing Information for ERLEADA[®].

Janssen Biotech, Inc.

© Janssen Biotech, Inc. 2020 April 2020
cp-49859v3

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Ischemic Cardiovascular Events (continued)

Ischemic cardiovascular events, including events leading to death, occurred in patients receiving ERLEADA[®]. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Consider discontinuation of ERLEADA[®] for Grade 3 and 4 events.

Fractures — In a randomized study (SPARTAN) of patients with nmCRPC, fractures occurred in 12% of patients treated with ERLEADA[®] and in 7% of patients treated with placebo. In a randomized study (TITAN) of patients with mCSPC, fractures occurred in 9% of patients treated with ERLEADA[®] and in 6% of patients treated with placebo. Evaluate patients for fracture risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents.

Falls — In a randomized study (SPARTAN), falls occurred in 16% of patients treated with ERLEADA[®] compared with 9% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Falls occurred in patients receiving ERLEADA[®] with increased frequency in the elderly. Evaluate patients for fall risk.

Seizure — In 2 randomized studies (SPARTAN and TITAN), 5 patients (0.4%) treated with ERLEADA[®] and 1 patient treated with placebo (0.1%) experienced a seizure. Permanently discontinue ERLEADA[®] in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLEADA[®]. Advise patients of the risk of developing a seizure while receiving ERLEADA[®] and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others.

Embryo-Fetal Toxicity — The safety and efficacy of ERLEADA[®] have not been established in females. Based on its mechanism of action, ERLEADA[®] can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of ERLEADA[®] [see *Use in Specific Populations (8.1, 8.3)*].

ADVERSE REACTIONS

Adverse Reactions — The most common adverse reactions ($\geq 10\%$) that occurred more frequently in the ERLEADA[®]-treated patients ($\geq 2\%$ over placebo) from the randomized placebo-controlled clinical trials (TITAN and SPARTAN) were fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, and fracture.

Laboratory Abnormalities — All Grades (Grade 3-4)

- Hematology** — In the TITAN study: white blood cell decreased ERLEADA[®] 27% (0.4%), placebo 19% (0.6%). In the SPARTAN study: anemia ERLEADA[®] 70% (0.4%), placebo 64% (0.5%); leukopenia ERLEADA[®] 47% (0.3%), placebo 29% (0%); lymphopenia ERLEADA[®] 41% (2%), placebo 21% (2%)
- Chemistry** — In the TITAN study: hypertriglyceridemia ERLEADA[®] 17% (3%), placebo 12% (2%). In the SPARTAN study: hypercholesterolemia ERLEADA[®] 76% (0.1%), placebo 46% (0%); hyperglycemia ERLEADA[®] 70% (2%), placebo 59% (1%); hypertriglyceridemia ERLEADA[®] 67% (2%), placebo 49% (0.8%); hyperkalemia ERLEADA[®] 32% (2%), placebo 22% (0.5%)

Rash — In 2 randomized studies, rash was most commonly described as macular or maculopapular. Adverse reactions of rash were 26% with ERLEADA[®] vs 8% with placebo. Grade 3 rashes (defined as covering $>30\%$ body surface area [BSA]) were reported with ERLEADA[®] treatment (6%) vs placebo (0.5%).

The onset of rash occurred at a median of 83 days. Rash resolved in 78% of patients within a median of 78 days from onset of rash. Rash was commonly managed with oral antihistamines, topical corticosteroids, and 19% of patients received systemic corticosteroids. Dose reduction or dose interruption occurred in 14% and 28% of patients, respectively. Of the patients who had dose interruption, 59% experienced recurrence of rash upon reintroduction of ERLEADA[®].

Hypothyroidism — In 2 randomized studies, hypothyroidism was reported for 8% of patients treated with ERLEADA[®] and 2% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. Elevated TSH occurred in 25% of patients treated with ERLEADA[®] and 7% of patients treated with placebo. The median onset was at the first scheduled assessment. There were no Grade 3 or 4 adverse reactions. Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted.

DRUG INTERACTIONS

Effect of Other Drugs on ERLEADA[®] — Co-administration of a strong CYP2C8 or CYP3A4 inhibitor is predicted to increase the steady-state exposure of the active moieties. No initial dose adjustment is necessary; however, reduce the ERLEADA[®] dose based on tolerability [see *Dosage and Administration (2.2)*].

Effect of ERLEADA[®] on Other Drugs — ERLEADA[®] is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of ERLEADA[®] with medications that are primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of activity if medication is continued. Concomitant administration of ERLEADA[®] with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in decreased exposure. Use caution if substrates of UGT must be co-administered with ERLEADA[®] and evaluate for loss of activity.

P-gp, BCRP, or OATP1B1 Substrates — Apalutamide is a weak inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Concomitant use of ERLEADA[®] with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP, or OATP1B1 must be co-administered with ERLEADA[®] and evaluate for loss of activity if medication is continued.

Please see accompanying full Prescribing Information for ERLEADA[®].